| Keywords: |
cancer chemotherapy; cancer survival; treatment response; leukemia; cancer surgery; cisplatin; cancer combination chemotherapy; treatment planning; note; paclitaxel; cancer patient; cancer radiotherapy; outcome assessment; antineoplastic agent; neoplasm; disease association; carboplatin; multiple cycle treatment; statistics; etoposide; heart disease; antineoplastic combined chemotherapy protocols; radiotherapy; editorial; radiation injury; oncology; bladder cancer; ifosfamide; vinblastine; survivor; cancer survivor; survivors; netherlands; neoplasms, radiation-induced; cardiovascular disease; cardiovascular risk; cardiovascular diseases; testis tumor; testicular neoplasms; bleomycin; neoplasms, germ cell and embryonal; neoplasms, second primary; second cancer; testis cancer; drug induced cancer
|
